[167] |
Apple stem pitting virus |
|
Detection |
Molecularly Imprinted Polymer Gel Laser Diffraction Sensor |
10 ng/mL |
MT32 protein |
DNA |
40 nt |
[168] |
bovine viral diarrhea virus |
BVDV type 1 |
Detection |
Gold nano sandwich sensor |
800 copies/mL |
Whole Virus |
DNA |
30 nt |
[169] |
Coronavirus |
SARS |
Detection |
Aptamer on Chip |
0.1 pg/mL |
nucleocapsid protein |
RNA |
92 nt |
[170] |
Norovirus |
Human noroviruse |
Detection |
ELASA |
|
NoV target-the P domain protein |
DNA |
|
[171] |
Norovirus |
GII.2 HuNoV strain, Snow Mountain Virus |
Detection |
|
Kd 191 nM |
Immobilized SMV |
DNA |
40 nt |
[172] |
Norovirus |
Murine Norovirus |
Detection |
Kd 290 nM G-quadruplexes |
20 aM to 120 aM |
Viral SELEX |
DNA |
40 nt |
[173] |
Porcine reproductive and respiratory syndrome virus |
VR-2332 |
Detection |
Kd 2.5 × 105 TCID50/mL |
In water 0.1 × 100–101 TCID50/mL Nasal/oral fluid 4.8 × 100–5.0 × 103 TCID50/mL |
Viral SELEX |
DNA |
40 nt |
[174] |
Vaccinia virus |
|
Detection |
Kd 26.3–40.9 nM |
In water 60 PFU in 30 μL in blood 150 to 900 PFU |
Viral SELEX |
DNA |
|
[175] |
vaccinia virus |
|
Detection |
Impedimetric |
60 virions in a microliter |
Virus Infected Cell SELEX |
DNA |
40 nt |
[176] |
vesicular stomatitis virus |
Oncolytic Virus |
Detection |
To protect the Virus from Nuetralizing antibodies |
53–86% degree of Protection |
Viral SELEX |
DNA |
40 nt |
[177] |
VSV |
vesicular stomatitis virus |
Detection |
aptamer-based affinity chromatography |
|
|
|
switchable aptamers |
[178] |
Apple stem pitting virus isolates |
|
Detection |
ELONA |
81% affinity |
MT32/PSA-H protein |
DNA |
20-80 nt |
[179] |
Bovine Herpes Virus-1 |
|
Detection/Therapy |
SELEX |
3.5 nM |
gD protein |
DNA |
38-51 nt |
[180] |
Dengue Virus |
|
Detection |
SELEX |
|
5’-UTR |
RNA |
|
[181] |
Human Papilloma virus (HPV) |
|
Detection |
SELEX |
10 nM |
type 16 VLP |
DNA |
|
[182] |
Iridovirus |
|
Detection |
ELISA |
nmol L−1
|
|
DNA |
71 nt |
[183] |
Parvovirus |
|
Detection |
SELEX |
467 nM |
|
DNA |
49 nt |
[184] |
Respiratory Syncytial Virus (RSV) |
|
Detection |
SELEX |
0.5 nM |
F protein |
DNA |
30 nt |
[185] |
Sindbis virus |
|
Detection |
ISH/RT-PCR |
High affinity |
E2 glycoprotein |
RNA |
|
[186] |
Alphavirus |
TC-83 Virus |
Therapy |
Replicon riobozyme actuator |
|
Vaccine |
RNA |
|
[187] |
Coronavirus |
SARS |
Therapy |
Just binding studies |
Kd 4–9 nM |
nucleocapsid protein |
DNA |
45 nt |
[188] |
Dengue |
|
Therapy |
|
|
DENV-2 envelop protein domain III (ED3) |
DNA |
15 nt |
[189] |
Dengue |
DENV-2 |
Therapy |
Thiolated aptamers |
Kd 154 nM |
envelope protein domain III |
DNA |
24 nt |
[190] |
Ebola |
VP35 |
Therapy |
Inhibition of VP35 |
10–50 nM |
Viral Protein 35 |
RNA |
45 nt |
[191] |
foot-and-mouth disease virus |
|
Therapy |
GFP tagged aptamers |
375 nM |
RNA-dependent RNA polymerase |
RNA |
30 nt |
[192] |
Hemorrhagic Septicemia Virus |
|
Therapy |
|
Viral plaques were reduced by 50%, cells were viable and healthy |
Viral SELEX |
RNA |
40 nt |
[193] |
Hirame Rhabdovirus |
|
Therapy |
|
15- to 63-fold reduction in plaques |
Viral SELEX |
RNA |
40 nt |
[194] |
HPV |
HPV-16 |
Therapy |
Binding Inhibition |
|
HPV-16 E7 protein |
RNA |
|
[195] |
HPV |
HPV-16 |
Therapy |
|
Kd = 0.05 pM |
HPV-16 L1 VLPs |
RNA |
15 nt |
[196] |
HPV |
HPV-16 |
Therapy |
Internalization of aptamers |
5 fold higher internalization |
HPV-16 E6/E7 transformed tonsillar epithelial cell SELEX |
RNA |
30 nt |
[197] |
Iridovirus |
Singapore grouper |
Therapy |
inhibition |
12.09 nM |
SGIV-infected GS cells |
DNA |
|
[198] |
Iridovirus |
Singapore grouper |
Therapy |
30% less mortality of fish |
|
Whole Virus |
DNA |
50 nt |
[199] |
Norovirus |
|
Therapy |
|
|
capsid protein VP1 |
DNA |
49 nt |
[200] |
rabies |
|
Therapy |
25–33% survival |
Kd 307 nM |
RABV glycoprotein |
DNA |
45 nt |
[201] |
rabies |
|
Therapy |
30–50% survival |
|
Cell SELEX |
DNA |
|
[202] |
rabies |
|
Therapy |
4 nmol PEG-FO24 protected 87.5% |
|
RABV-infected BHK-21 |
DNA |
45 nt |
[203] |
rabies |
|
Therapy |
|
Kd 28–39 nM |
Virus infected Cell SELEX |
DNA |
45 nt |
[204] |
Rift Valley fever virus |
|
Therapy |
|
|
nucleocapsid protein |
RNA |
30 nt |
[205] |
xenotropic murine leukemia virus-related virus (XMRV) |
Different from HIV-1 |
Therapy |
IC50 2 nM |
|
XMRV RT |
RNA |
three 12 nt sequences |